Design and baseline characteristics for the aminoguanidine clinical trial in overt type 2 diabetic nephropathy (ACTION II)

Controlled Clinical Trials

Volumn 20, Issue 5, 1999, Pages 493-510

  Freedman, Barry I ^a   Wuerth, Jean Paul ^b   Cartwright, Kenneth ^b   Bain, Raymond P ^c   Dippe, Stephen ^f   Hershon, Kenneth ^f   Mooradian, Arshag D ^d   Spinowitz, Bruce S ^e  

^a WAKE FOREST BAPTIST HEALTH   (United States)

^b Alteon Inc   (United States)

^c GEORGE WASHINGTON UNIVERSITY   (United States)

^d SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^f NONE

Author keywords

Advanced glycation endproduct inhibitors; Aminoguanidine; Chronic kidney failure; Clinical trial; Diabetes mellitus; Diabetic nephropathy

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMINOGUANIDINE; ASPARTATE AMINOTRANSFERASE; C PEPTIDE; CREATININE; GLUCOSE; HEMOGLOBIN A1C; IOTALAMIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DIABETIC NEUROPATHY; DOUBLE BLIND PROCEDURE; EYE PHOTOGRAPHY; FEMALE; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HEALTH CARE COST; HUMAN; KIDNEY BIOPSY; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MULTICENTER STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; FEMALE; GUANIDINES; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PATIENT SELECTION; QUALITY OF LIFE; QUESTIONNAIRES; RESEARCH DESIGN;

EID: 0032857820     PISSN: 01972456     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-2456(99)00024-0     Document Type: Article

References (41)

1. Raskin P., Rosenstock J. Blood glucose control and diabetic complications. Ann Intern Med. 105:1986;254-263.
2. Raskin P. Diabetic regulation and its relationship to microangiopathy. Metabolism. 27:1978;235-251.
3. Brownlee M., Cerami A., Vlassara H. Advanced glycosylation and the pathogenesis of diabetic complications. Ann Intern Med. 101:1984;527-537.
4. Brownlee M., Cerami A., Vlassara H. Advanced glycosylation end products in tissues and the biochemical basis of diabetic complications. N Engl J Med. 318:1988;1315-1321.
5. Brownlee M. Glycation of macromolecules. Alberti K.G.M.M., De Fronzo R.A., Keen H.et al. International Textbook of Diabetes Mellitus. 1992;Wiley, New York.
6. Makita Z., Radoff S., Rayfield E.J.et al. Advanced glycosylation end product in patients with diabetic nephropathy. N Engl J Med. 325:1991;836-842.
7. Edelstein D., Brownlee M. Mechanistic studies of advanced glycosylation end product inhibition by aminoguanidine. Diabetes. 41:1992;26-29.
8. Soulis-Liparota T., Cooper M., Papazoglou D.et al. Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes. 40:1991;1328-1334.
9. Ellis E.N., Good B.H. Prevention of glomerular basement membrane thickening by aminoguanidine in experimental diabetes mellitus. Metabolism. 40:1991;1016-1019.
10. Edelstein D., Brownlee M. Aminoguanidine ameliorates albuminuria in diabetic hypertensive rats. Diabetologia. 35:1992;96-97.
11. Itakura M., Yoshikawa H., Bannai C.et al. Aminoguanidine decreases urinary albuminuria and high-molecular-weight proteins in diabetic rats. Life Sci. 49:1991;889-897.
12. Crowley S.T., Brownlee M., Edelstein D.et al. Effects of nonenzymatic glycosylation of mesangial matrix on proliferation of mesangial cells. Diabetes. 40:1991;540-547.
13. Clinical Investigator's Brochure. Aminoguanidine Hydrochloride, (Alteon Inc. Internal Document) Revised September, 1993.
14. Lewis E.J., Hunsicker L.G., Bain R.P.et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 329:1993;1456-1462.
15. Cockcroft D.W., Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron. 16:1976;13.
16. 125I-iothalamate. Kidney Int. 4:1973;346-349.
17. Matts J.P., Lachin J.M. Properties of permuted-block design in clinical trials. Control Clin Trials. 9:1988;327-344.
18. Lachin J.M., Foulkes M. Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification. Biometrics. 42:1986;507-519.
19. National High Blood Pressure Education Program (NHBPEP) Working Group Report on Hypertension and Chronic Renal Failure. NIH Publication No. 90-3032. Washington, DC: U.S. Government Printing Office; August 1990.
20. Bakris G.L., Copley J.B., Vicknair N.et al. Calcium channel blockers versus other antihypertensive therapies of progression on NIDDM associated nephropathy. Kidney Int. 50:1996;1641-1650.
21. Standards of medical care for patients with diabetes mellitus. Diabetes Care 1992;15(suppl 2):10-13.
22. Nutritional recommendations and principles for individuals with diabetes mellitus. Diabetes Care 1992;15(suppl 2):21-28.
23. Insulin administration. Diabetes Care 1992;12(suppl 2):30-33.
24. Detection and management of lipid disorders in diabetes. Diabetes Care 1995;18(suppl 1):86-93.
25. Ware J.E. Jr., Sherbourne C.D. The MOS 36-item short form health survey (SF-36). Med Care. 30:1992;472.
26. Ware J.E. Jr. SF-26 Health Survey Manual and Interpretation Guide. 1993;Nimrod Press, Westwood, Massachusetts.
27. Torrance GW, Zhang Y, Feeny DH, et al. Multi-attribute preference functions for a comprehensive health status classification system. McMaster University, Hamilton, Ontario, Centre for Health Economics and Policy Analysis, Working Paper No. 92-118, 1992.
28. Drummond M.F., Sotoddart G.L., Torrance G.W. Methods for the Economic Evaluation of Health Care Programs. 1987;Oxford Medical Publications, New York.
29. Manning W.G., Fryback D.G., Weinstein M.C. Reflecting uncertainty in cost-effectiveness analysis. Gold M.R., Seigel J.E., Russel L.B.et al. Cost Effectiveness in Health and Medicine. 1996;Oxford University Press, New York.
30. Peduzzi P., Wittes J., Detre K.et al. Analysis as-randomized and the problem of non-adherence. an example from the Veterans Affairs randomized clinical trial of coronary artery bypass surgery Stat Med. 12:1993;1185-1195.
31. Lee E.T. Statistical Methods for Survival Data Analysis. 1992;Wiley, New York.
32. Kalbfleisch J.D., Prentice R.L. The Statistical Analysis of Failure Time Data. 1980;Wiley, New York.
33. Cox D.R. Regression models and life tables. J Roy Stat Soc. 34(B):1972;187-220.
34. Lagakos S.W., Lim L.L., Robins J.M. Adjusting for early treatment-termination in comparative clinical trials. Stat Med. 9:1990;1417-1424.
35. Fleiss J.L., Bigger J.T., McDermott M.et al. Nonfatal myocardial infarction is, by itself, an inappropriate endpoint in clinical trials in cardiology. Circulation. 81:1990;684-685.
36. Laird N.M., Ware J.H. Random-effects models for longitudinal data. Biometrics. 38:1982;963-974.
37. Jennrich R.I., Schluchter M.D. Unbalanced repeated-measures models with structured covariance matrices. Biometrics. 42:1986;805-820.
38. Lachin J.M. Some large sample distribution-free estimators and tests of multivariate partially incomplete data from two populations. Stat Med. 11:1992;1151-1170.
39. Lan K.K.G., DeMets D.L. Discrete sequential boundaries for clinical trials. Biometrika. 64:1983;191-199.
40. Lan K.K.G., Lachin J.M. Implementation of group sequential logrank tests in a maximum duration trial. Biometrics. 46:1990;759-770.
41. O'Brien P.C., Fleming T.R. A multiple testing procedure for clinical trials. Biometrics. 35:1979;549-556.